Kidney cancer characteristics and genotype-phenotype-correlations in Birt-Hogg-Dube syndrome by Sattler, Elke C. et al.
RESEARCH ARTICLE
Kidney cancer characteristics and genotype-
phenotype-correlations in Birt-Hogg-Dube´
syndrome
Elke C. Sattler1, Marlene ReithmairID2, Ortrud K. SteinleinID2*
1 Department of Dermatology and Allergology, University Hospital, LMU Munich, Munich, Germany,
2 Institute of Human Genetics, University Hospital, LMU Munich, Munich, Germany
* Ortrud.Steinlein@med.uni-muenchen.de
Abstract
Birt-Hogg-Dube´ syndrome (BHDS) is a genetic tumor syndrome characterized by lung
cysts, pneumothorax, fibrofolliculomas and renal cell cancer. The diagnosis of BHDS is usu-
ally considered if kidney cancer occurs before age 50 years, is multifocal and/or bilateral or
of the oncocytoma/hybrid oncocytoma-chromophobe type. Using a sample of 50 BHDS
families with a total of 178 patients we analyzed how many kidney cancer patients fulfilled
one or more of these criteria. Furthermore, we addressed the question if genotype-pheno-
type-correlations exist that can be used for risk stratification. Renal cell cancer occurred in
34/178 (19.1%) patients, and the reported male bias was not observed. Furthermore, most
kidney malignancies occurred after the age of 50 years. Thus, the majority of tumors did not
show the typical hallmarks of BHDS. A below-average tumor frequency (17.2%) was
observed for the known mutational hotspot c.1285delC/dupC that was the cause of BHDS in
24% of families. Unexpected was the high tumor frequency (66.7%) associated with muta-
tion c.887C>G within a single family, a finding that merits further exploration.
Introduction
Birt-Hogg-Dube´ syndrome (BHDS, [MIM: 135150]) is an autosomal dominant tumor syn-
drome caused by mutations in the folliculin-encoding FLCN gene [1–4]. The disorder is char-
acterized by symptoms affecting mainly skin, lung and kidneys that demonstrate high inter-
and intrafamilial variability [5]. About 85% of the patients are found to have lung bullae that
cause pneumothorax in about 25–30% of them [6]. Common skin symptoms in adult patients
are benign hair follicle tumours named fibrofolliculomas that mainly develop on the face and
neck, often steadily increasing in number and size during life time. A serious complication is
renal cell cancer (RCC) that, in contrast to sporadic RCC, shows a strong trend towards multi-
focal and or bilateral manifestation. Histologically different types of kidney tumors are found,
including clear cell, hybrid oncocytoma/chromophobe or papillary RCC. The reported life
time risks for RCC in BHDS patients are between 14–35% [7–10]. Compared to the frequency
of RCCs in the general population these risks are significantly increased. However they are
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lower than, for example, the 15–74% colon cancer risk in HNPCC (hereditary non polyposis
colon cancer) or the 85% thyroid cancer risk in MEN2a (multiple endocrine neoplasia type 2a)
[11]. The reasons behind the moderate RCC penetrance in BHDS are so far unknown. It is
also mostly unknown which genetic or environmental factors modulate the tumor risk that
leaves the majority of BHDS patients unaffected but cause multifocal and/or bilateral RCC in
others. Previous studies have already presented data about RCC risks and FLCN mutations but
did not focus specifically on genotype-phenotype-correlations [12]. In the present study we
therefore analyzed possible genotype-phenotype-correlations that might affect RCC pene-
trance in BHDS patients. We indeed found correlations that are suggestive of increased tumor
risks for certain BHDS patients. Furthermore, we demonstrate that only a minority of BHDS
patients develops one or more of the clinical features that are regarded as typical for this inher-
ited tumor syndrome.
Materials and methods
Patients
All research was conducted according to the declaration of Helsinki principles. The study has
been approved of by the ethical committee/institutional review board (IRB) of the Medical
Faculty, University Hospital Munich, under the project-number: 489/16UE. Informed consent
was obtained from all individuals participating in DNA testing. Detailed clinical data were
obtained from 178 BHDS patients (male 86, female 92) belonging to 50 unrelated families. A
subset of 83 patients was available for germline FLCN testing, and additional family members
were only included if they had at least two major BHD symptoms or were obligate carriers. 42
families were of German origin, one each from Turkey, Switzerland and Greece, two from
Great Britain and three of Eastern European origin with German roots. Only family members
>18 years of age were included because children are usually not tested for BHDS and rarely
develop the typical symptoms.
Genetic testing
The complete FLCN gene coding region including adjacent intronic sequences was screened for
mutations by PCR and subsequent Sanger sequencing following standard protocols (for primer
details and PCR protocols see S1 Table). For each PCR 50–100 ng DNA were amplified using the
HotStarTaq DNA Polymerase and InvitrogenTMTaq DNA Polymerase recombinant (Qiagen,
Hilden, Germany; Thermo Fisher Scientific, Dreieich, Germany). Purification of the amplifica-
tion products was performed with the Qiagen PCR purification kit (Qiagen, Hilden, Germany),
and PCR products were sequenced using the 3500 Genetic Analyser (Thermo Fisher Scientific,
Dreieich, Germany). MLPA (multiplex ligation-dependent probe amplification) was performed
using the SALSA MLPA P256 FLCN probemix (MRC Holland, Amsterdam, The Netherlands)
according to the manufacturer’s protocol on the ABI 3100 Avant (Applied Biosystems, Darm-
stadt, Germany) and analyzed by Coffalyser.Net software (MRC Holland, Amsterdam, The
Netherlands). Statistical analyses were performed using the two-tailed Mann-Whitney U Test
and the Chi-square Test.
Results
RCCs were diagnosed in 20/50 BHDS pedigrees (40.0%). In 7/20 (35.0%) of these families
more than one family member was affected. RCCs were diagnosed in 34 patients, and were
bilateral (synchron or metachron) in at least six of them. No sex differences were observed
regarding the number of BHDS patients that developed RCCs (females 17/34 (50.0%) versus
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males 17/34 (50.0%), or with respect to the age at initial diagnosis (female: median 54.5 years,
range 42 years; male: median 57.0 years, range 50 years; Z-Score -0.58199, U-value 97.5, p .56).
The average age of onset is well below that of sporadic RCC (61.8 years) [12–16–17](Table 1).
Previously BHDS families have been reported that showed a RCC-only phenotype without fur-
ther typical symptoms [14]. None of our 50 families showed this phenomenon; they all had at
least one family member with fibrofolliculomas or pneumothorax.
As demonstrated in Fig 1, a total of 33 different FLCN germline mutations were found. The
heterozygous mutations were either frame shifting or truncating and are predicted to result in
Table 1. Patients with RCCs: Histological type and age of diagnosis.
Patient ID1 Histology Age (y) Sex
BHD15-II1 NA 72 M
BHD15-III1 NA 30 M
BHD15-IV1 hybrid oncocytoma/chromophobe RCC, unilateral 45 M
BDH17-II1 NA 65 M
BHD20-II1 chromophobe RCC, multiple unilateral 56 F
BHD20-II4 chromophobe RCC, single 56 F
BHD20-III5 hybrid oncocytoma/chromophobe RCC, unilateral 37 F
BHD21-III3 clear cell RCC bifocal unilateral, 49 F
BHD23-III1 chromophobe RCC, bilateral 46 F
BHD23-IV1 NA, bilateral NN M
BHD24-III3 NA 70 F
BDH26-IV2 clear cell RCC, unilateral 43 M
BDH26-IV3 NN 43 F
BHD28-III3 NA NN M
BHD30-III3 chromophobe RCC, bilateral multiple 50 M
BHD31-III4 chromophobe, unilateral 55 F
BHD33-III5 clear cell RCC, unilateral 35 M
BHD33-IV5 clear cell RCC, bilateral, metachron 69+79 M
BHD35-II2 NA NN F
BHD36-IV8 NA NN M
BHD38-II2 NA 59 F
BHD38-III2 NA 72 F
BHD38-IV2 chromophobe RCC, unilateral 56 F
BHD40-II3 clear cell RCC, bilateral 80 M
BHD45-II7 NA 46 F
BHD45-II9 clear cell RCC, unilateral 79 F
BHD45-III3 bilateral, metastatic 66 M
BHD45-II7 hybrid oncocytoma/chromophobe, unilateral 64 M
BHD45-II7 NN 57 M
BHD45-II7 papillary, unilateral 54 F
BHD46-III1 clear cell, bilateral
hybrid papillary/chromophobe, unilateral
45
57
F
BHD47-IV2 hybrid oncocytoma/chromophobe, unilateral 39 F
BHD48-II4 NN 57 M
BHD50-IV5 clear cell, unilateral 50 M
1 Given are the family ID followed by the pedigree number. NA, not available because diagnosis was made >10 years
ago which is the statutory period of retention for medical documents. NN, patient did not agree to make medical
reports available.
https://doi.org/10.1371/journal.pone.0209504.t001
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nonsense mediated decay or in a nonfunctional protein. The FLCN mutations were distributed
over all but one (exon 10) of the 11 coding exons. In one family that was clinically diagnosed
with typical BHDS no FLCN mutation was detectable. These results are in accordance with the
reported mutation detection rates of 81–96% [12–13,18].
The tumors were associated with 16 distinct mutations in 9 different exons. At a first glance
RCCs seemed to be disproportionately often associated with mutations in exon 11. However,
Fig 1. FLCN mutations and kidney cancer. Schematic presentation of coding (black bars) and non-coding (grey bars) FLCN exons. The positions of germline mutations
detected in the BHDS sample are given. Mutations associated with RCCs are given in bold. Square brackets contain the numbers of patients that developed RCC, followed
by the total number of BHDS patients. Exon numbering is shown at the bottom.
https://doi.org/10.1371/journal.pone.0209504.g001
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this exon contains a known mutational hotspot (NM_144997.6: c.1285C) that in our sample
was the cause of BHDS in 12/50 pedigrees [13,19]. Taking the total number of patients per
exon into consideration the RCC frequency for exon 11 was actually lower than that of most
other exons (17.2%, compared to 20.0% for exon 5 or 23.8% for exon 6).
We were not able to confirm previous reports that described an up to 2.5 fold increase of
RCCs in male compared to female BHDS patients [12–15]. There were no differences regard-
ing the age at which an RCC was diagnosed between mutations located in the 5’- or 3’-part of
the FLCN gene (51.9±13.2 vs 55.3±10.7 years, Z-Score -0.75056, U-value 58.5, p 0.45326).
However, the position of the mutation within the gene might be a factor influencing cancer
risk. This would be unlikely in disorders that are caused by haploinsufficiency, because all
mutations would result in the same loss of function. However, it could be an important factor
if the mutated FLCN mRNA is translated and the truncated protein acts in a dominant nega-
tive manner. Proteins truncated within the 5’ part or 3’part differ with respect to their total
length and remaining functional domains. So far it is not sure which of the two mechanisms
applies to FLCN, which renders it reasonable to investigate possible phenotype differences
between 5‘and 3‘mutations. The frequency of RCCs with respect to the total number of
patients per exon showed a higher RCC rate for patients with a mutation located in the 5’ part
(exon 4–8, 14/69 patients, 20.3%, total subgroup: 56.1±16.2 years) compared to those with a
mutation in the 3’ part (exon 10–14, 13/93 patients; 14.0%, total subgroup: 57.4±16.3 years) of
FLCN (p-value 0.30, odds ratio 1.56197, 95% CI 0.63–3.92). These differences are not signifi-
cant; larger samples are needed to decide if genotype-phenotype correlations exist with respect
to the intragenic position of mutations.
Discussion
Exon 9 was not included in the genotype-phenotype analysis because it would have distorted
the results. Mutation FLCN c.887C>G in exon 9 stands out because it was found in a family
(BHD45) in which six out of nine (66.7%) patients developed RCCs. This unusually high rate
of RCC might be due to unknown genetic or environmental risk factors within this specific
family, but a true genotype-phenotype effect can also not be excluded yet. It therefore seems
prudent to look out for additional families carrying this specific FLCN mutation.
It has been suggested that BHDS (as well as other genetic tumor syndromes) should be con-
sidered if an RCC occurs before age 50 years [17]. However in our sample 16/25 (64.0%)
patients were diagnosed with RCC at age 50 years or older (only patients included for which
this information was available). The criterion ‘age’ alone would have therefore been insuffi-
cient as an identifier for BHDS. Adding the criterion ‘bilateral or multifocal RCC’ would have
raised a red flag only for six patients from the 50+ age group (37.5%). Bilateral or multifocal
tumor presentation also was not a common finding in the 18–49 years age group (37.5%). The
diagnostic criteria proposed by the European BHDS Consortium also include RCC histology,
with a chromophobe or hybrid chromophobe-oncocytoma cancer subtype being considered
suspicious of BHDS [7]. Previous reports found the chromophobe tumor type in about 34% of
BHDS-RCCs, which is a good match for the 38.1% frequency this tumor type had in our sam-
ple [12,15,20–21]. However, the hybrid chromophobe-oncocytoma cancer subtype was
reported to have a 50% frequency in BHDS-RCCs but in our sample only 19.1% of RCCs for
which histological information was available showed this subtype [22]. The clear cell RCC
(47.6%) was the most common histological subtype in our sample. These findings deviate
from earlier reports in which clear cell RCCs only accounted for about 9% of all renal tumors
in BHDS patients [12,15,20, 22–23]. These discrepancies could very well point towards a meth-
ological problem. Chromophobe tumors are prone to be misdiagnosed as clear cell RCCs if
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not analysed by specialised uropathologists. It would therefore have been preferable to have all
tumor samples analysed by the same team of specialists. Unfortunately this was not managable
because many tumor samples were no longer available and we often had to rely on the written
reports. It is therefore questionable whether our numbers reflect the true frequencies of the dif-
ferent RCC subtypes. On the other hand ascertainment bias regarding the published frequen-
cies cannot be excluded. Unusual RCC subtypes such as hybrid chromophobe-oncocytomata
are more likely to result in a referral to a BHDS centre, resulting in an overestimation of this
RCC subtype. This bias probably also exists in our sample, however, the majority of our
patients was referred to our BHDS centre because of their dermatological or pneumological
health problems and are therefore unlikely to be profoundly affected by this bias. Another con-
tributing factor could be that clear cell-like cytoplasm and prominent perinuclear halo are fre-
quent features in different types of RCC in BHDS. These features can be misinterpreted in
routine histopathological assessment, resulting in overrepresentation of clear cell RCC diagno-
sis [23].
BHDS patients have substantial health risks but regular radiological and dermatological
check-ups can considerably lower their morbidity and mortality rates. It is therefore crucial
that the diagnosis of BHDS is made as early as possible and that the index patient is encour-
aged to inform the family members about the possibility of genetic counselling and predictive
testing. In our sample the criteria age of onset >50 years, chromophobe/hybrid chromophobe-
oncocytoma tumor histology or multifocal/bilateral tumor localisation would have raised sus-
picion of BHDS only in a minority of patients. This emphasizes that an interdisciplinary
approach is needed to identify patients with this rare tumor syndrome. The most effective
approach includes a careful dermatological inspection, a medical history focusing on renal and
pulmonary problems and a thorough pedigree analysis covering at least three generations.
This approach greatly increases the chances to recognize patterns of symptoms in multisystem
disorders such as BHDS. Genetic testing can then be used to confirm the diagnosis in the
index patient by detecting the underlying FLCN mutation. Once known this mutation offers
the chance to identify additional family members at risk. The intragenic location of the FLCN
mutation does not yet influence tumor screening strategies or treatment planning. The poten-
tial use of genotype-phenotype correlations for the improvement of patient care needs to be
analyzed in independent BHDS samples.
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